Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Benralizumab Completely Depletes Gastrointestinal Tissue Eosinophils and Improves Symptoms in Eosinophilic Gastrointestinal Disease
Fei Li Kuang, Michelly Sampaio De Melo, Michelle Makiya, et al.
The Journal of Allergy and Clinical Immunology In Practice (2022) Vol. 10, Iss. 6, pp. 1598-1605.e2
Open Access | Times Cited: 53

Showing 1-25 of 53 citing articles:

Eosinophil Depletion with Benralizumab for Eosinophilic Esophagitis
Marc E. Rothenberg, Evan S. Dellon, Margaret H. Collins, et al.
New England Journal of Medicine (2024) Vol. 390, Iss. 24, pp. 2252-2263
Closed Access | Times Cited: 30
World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management
William Shomali, Jason Gotlib
American Journal of Hematology (2024) Vol. 99, Iss. 5, pp. 946-968
Open Access | Times Cited: 18
Biologics in eosinophilic gastrointestinal diseases
Evan S. Dellon, Jonathan M. Spergel
Annals of Allergy Asthma & Immunology (2022) Vol. 130, Iss. 1, pp. 21-27
Open Access | Times Cited: 54
Benralizumab for eosinophilic gastritis: a single-site, randomised, double-blind, placebo-controlled, phase 2 trial
Kara Kliewer, Cristin Murray-Petzold, Margaret H. Collins, et al.
˜The œLancet. Gastroenterology & hepatology (2023) Vol. 8, Iss. 9, pp. 803-815
Open Access | Times Cited: 40
Benralizumab does not elicit therapeutic effect in patients with chronic spontaneous urticaria: results from the phase IIb multinational randomized double-blind placebo-controlled ARROYO trial
Sabine Altrichter, Ana M. Giménez‐Arnau, Jonathan A. Bernstein, et al.
British Journal of Dermatology (2024) Vol. 191, Iss. 2, pp. 187-199
Open Access | Times Cited: 14
Efficacy of anti-interleukin 5 therapy in hypereosinophilic syndrome: An updated systematic review and meta-analysis
Saad Masood, M. Paracha, Sophia Ahmed, et al.
Allergy and Asthma Proceedings (2025) Vol. 46, Iss. 2, pp. e24-e32
Closed Access | Times Cited: 1
The role of biologics in pediatric food allergy and eosinophilic gastrointestinal disorders
Sayantani Sindher, Suzanne Barshow, Jyothi Tirumalasetty, et al.
Journal of Allergy and Clinical Immunology (2023) Vol. 151, Iss. 3, pp. 595-606
Open Access | Times Cited: 22
Current and Novel Therapies for Eosinophilic Gastrointestinal Diseases
Giovanni Marasco, Pierfrancesco Visaggi, Mariagiulia Vassallo, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 20, pp. 15165-15165
Open Access | Times Cited: 16
Interleukin‐5 as a pleiotropic cytokine orchestrating airway type 2 inflammation: Effects on and beyond eosinophils
Kathleen M. Buchheit, Dominick Shaw, Geoffrey Chupp, et al.
Allergy (2024) Vol. 79, Iss. 10, pp. 2662-2679
Open Access | Times Cited: 6
Living without eosinophils: evidence from mouse and man
David J. Jackson, Ian Pavord
European Respiratory Journal (2022) Vol. 61, Iss. 1, pp. 2201217-2201217
Open Access | Times Cited: 22
Review article: Emerging insights into the epidemiology, pathophysiology, diagnostic and therapeutic aspects of eosinophilic oesophagitis and other eosinophilic gastrointestinal diseases
Eric E. Low, Evan S. Dellon
Alimentary Pharmacology & Therapeutics (2023) Vol. 59, Iss. 3, pp. 322-340
Closed Access | Times Cited: 11
Biologics and Hypereosinophilic Syndromes: Knowledge Gaps and Controversies
Fei Li Kuang, Paneez Khoury, Peter F. Weller, et al.
The Journal of Allergy and Clinical Immunology In Practice (2023) Vol. 11, Iss. 9, pp. 2666-2671
Closed Access | Times Cited: 10
Treatment of eosinophilic esophagitis: literature review and own clinical observations
V. O. Kaybysheva, Е. Д. Федоров, Sergey Georgievich Shapovaliantc
Russian Journal of Allergy (2025)
Closed Access
Effect of Biologics against Interleukin-5 Administered to Patients with Eosinophilic Gastroenteritis<sup>1</sup>
Kazuya Miyaguchi, Hisashi Matsumoto, Rie Shiomi, et al.
Internal Medicine (2025)
Open Access
Therapeutic Challenges and Emerging Strategies for T674I and PTPN11 Mutations in a FIP1L1-PDGFRA-Positive Myeloproliferative Neoplasm: A Case Report
Sıdıka Gülkan Özkan, Ali Kimiaei, Seyedehtina Safaei, et al.
Life (2025) Vol. 15, Iss. 3, pp. 505-505
Open Access
Recent advances in understanding the role of eosinophils
Gregory Constantine, Amy D. Klion
Faculty Reviews (2022) Vol. 11
Open Access | Times Cited: 16
Current state of biologics in treating eosinophilic esophagitis
Quan M. Nhu, Seema S. Aceves
Annals of Allergy Asthma & Immunology (2022) Vol. 130, Iss. 1, pp. 15-20
Open Access | Times Cited: 16
The minichromosome maintenance complex drives esophageal basal zone hyperplasia
Mark Rochman, Yrina Rochman, Julie M. Caldwell, et al.
JCI Insight (2023) Vol. 8, Iss. 17
Open Access | Times Cited: 9
Pharmacologic Management of Eosinophilic Esophagitis
Gary W. Falk, Robbie Pesek
Immunology and Allergy Clinics of North America (2024) Vol. 44, Iss. 2, pp. 245-264
Closed Access | Times Cited: 3
Biologic therapy in rare eosinophil-associated disorders: remaining questions and translational research opportunities
Paneez Khoury, Florence Roufosse, Fei Li Kuang, et al.
Journal of Leukocyte Biology (2024)
Open Access | Times Cited: 3
Urine eosinophil‐derived neurotoxin: A potential marker of activity in select eosinophilic disorders
Michelle Makiya, Paneez Khoury, Fei Li Kuang, et al.
Allergy (2022) Vol. 78, Iss. 1, pp. 258-269
Open Access | Times Cited: 14
Eosinophilic Gastrointestinal Diseases Beyond the Esophagus: An Evolving Field and Nomenclature.
Walker D. Redd, Evan S. Dellon
PubMed (2022) Vol. 18, Iss. 9, pp. 522-528
Closed Access | Times Cited: 14
Dupilumab Leads to Clinical Improvements including the Acquisition of Tolerance to Causative Foods in Non-Eosinophilic Esophagitis Eosinophilic Gastrointestinal Disorders
Naoya Arakawa, Hisako Yagi, Mariko Shimizu, et al.
Biomolecules (2023) Vol. 13, Iss. 1, pp. 112-112
Open Access | Times Cited: 8
Clinical and Therapeutic Intervention of Hypereosinophilia in the Era of Molecular Diagnosis
Lynh Nguyen, Aditi Saha, Andrew Kuykendall, et al.
Cancers (2024) Vol. 16, Iss. 7, pp. 1383-1383
Open Access | Times Cited: 2
Successful Introduction of Benralizumab for Eosinophilic Ascites
Nabil Belfeki, N. Ghriss, Souheil Zayet, et al.
Biomedicines (2024) Vol. 12, Iss. 1, pp. 117-117
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top